Search

Displaying results 11 - 20 of 26 in total
  1. Drug

    Efanesoctocog alfa

    go.drugbank.com/drugs/DB16662
    ApprovedInvestigational

    [A257464,A257469] In February 2023, efanesoctocog alfa was approved by the FDA as a new class of factor VIII therapy for hemophilia A.[L45379,L45414] … Efanesoctocog alfa (BIVV001) is a recombinant factor VIII (FVIII) analogue fusion protein used for the routine prophylaxis, perioperative management of bleeding and on-demand treatment and control of bleeding

    Synonyms: Antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtlCategories: Factor VIII, Biological Factors
  2. Drug

    Turoctocog alfa pegol

    go.drugbank.com/drugs/DB14738
    ApprovedInvestigational

    Fundamentally, the N8-GP moiety is identical to [turoctocog alfa], a recombinant human clotting factor VIII (rFVIII) with a truncated B-domain made from the sequence coding for 10 amino acids from the … This modification to the general turoctocog alfa rFVIII structure makes N8-GP an extended half-life factor VIII molecule for factor VIII replacement therapy in patients with factor VIII deficiency, or

    Categories: Factor VIII, Biological FactorsSynonyms: Antihemophilic factor (recombinant), glycopegylated-exei
  3. Drug

    Beroctocog alfa

    go.drugbank.com/drugs/DB14473
    ApprovedInvestigational

    Categories: Human Antihemophilic Factors, Factor VIIISynonyms: Factor VIII
  4. Drug

    Omfiloctocog alfa

    go.drugbank.com/drugs/DB19229
    Investigational

    Omfiloctocog alfa is under investigation in clinical trial NCT03947567 (Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia a Patients.).

    Synonyms: HUMAN COAGULATION FACTOR VIII (FVIII, ANTIHEMOPHILIC FACTOR, AHF, PROCOAGULANT COMPONENT) WITH DELETED B-DOMAIN (746-1639)-SEQUENCE: SINGLE-CHAIN RECOMBINANT FVIII COMPOSED OF DOMAINS A1-A1-A2-A2 (1-740, FACTOR VIII (RECOMBINANT HUMAN SCT800 LIGHT
  5. Pathway

    Antihemophilic Factor Human Action Pathway

    smpdb.ca/view/SMP0126841
    Drug action

    Antihemophilic factor human, also known as Hemofil, Koate, and Wilate is used as factor VIII replacement therapy to treat hemophilia A. … Administered intravenously the antihemophilic factor human replaces the abnormal coagulation factor VIII, acting as a cofactor to activate coagulation factor IX and X.

    Drugs: Calcium · Antihemophilic factor human
    Enzymes: Tissue factor, Coagulation factor VIII
  6. Pathway

    Antihemophilic Factor Human Recombinant Action Pathway

    smpdb.ca/view/SMP0126774
    Drug action

    Antihemophilic factor, human recombinant is administered intravenously and acts to correct coagulation defects, by activating coagulation factor X and IX. … Antihemophilic factor, human recombinant of the coagulation Factor VIII, also known as Advate, Adynovate, Helixate, Kogenate, Kovaltry, Novoeight, Recombinate, to treat hemophilia A, von Willebrand disease

    Drugs: Antihemophilic factor, human recombinant · Calcium
    Enzymes: Tissue factor, Coagulation factor VIII
  7. Indication

    Acquired Coagulation Factor Deficiency caused by Vitamin K Antagonist

    go.drugbank.com/conditions/DBCOND0165667
    Drugs: Coagulation Factor IX Human
    Synonyms: Acquired Coagulation Factor Deficiency caused by Vitamin K Antagonist
  8. Target

    Coagulation factor VIII

    go.drugbank.com/bio_entities/BE0000016
    TargetCarrierEnzymeHumans

    Factor VIII, along with calcium and phospholipid, acts as a cofactor for F9/factor IXa when it converts F10/factor X to the activated form, factor Xa

    Polypeptides: Coagulation factor VIIISynonyms: Antihemophilic factor
  9. Drug

    Simoctocog alfa

    go.drugbank.com/drugs/DB09108
    Approved

    It is an antihemorrhagic agent used as a replacement therapy in individuals with Haemophilia A who lack the factor VIII in the intrinsic pathway of blood coagulation system. … Full human post-translational modifications via elimination of potentially immunogenic glycosylation patterns found in non-human cell lines led to decreased immunogenicity and longer half-life [A31525]

  10. Drug

    Damoctocog alfa pegol

    go.drugbank.com/drugs/DB14700
    ApprovedInvestigational

    In recent years, various extended half-life factor VIII and factor IX preparations have been studied and gained approval. … [A38907] Also known as, BAY94-9027, Damoctocog alfa pegol is a longer-acting Factor VIII therapy formulated with polyethylene glycol (PEG) to reduce the number of infusions necessary to prevent bleeds

    Categories: Blood Coagulation Factors